Authors: Ranjbar K, Shahriarad R, erfani A, Khodamoradi Z, Saadi MH PMID: 33838657 PMCID: PMC8035859 DOI: 10.1186/s12879-021-06045-3 Abstract Background: Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the [...]

Authors: Ramakrishnan S, Nicolau DV, Langford B, Mahdi M, Jeffers H, Mwasuku C et al. PMID: 33844996 PMCID: PMC8040526 DOI: 10.1016/S2213-2600(21)00160-0 Abstract Background: Multiple early reports of patients admitted to hospital with COVID-19 showed that patients with chronic respiratory disease were significantly under-represented in these cohorts. We hypothesised that the widespread use of inhaled glucocorticoids [...]

Authors: Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J PMID: 33833065 PMCID: PMC8666823 DOI: 10.1136/gutjnl-2021-324090 Abstract We read with great interest the recent article published in Gut in which Yeoh et al demonstrated that gut microbiota composition of recovered patients with COVID-19 remained significantly distinct from uninfected controls. Persisting symptoms, also [...]

Authors: Rashid RA, Zgair A, Al-Ani R PMID: 33839489 PMCID: PMC8024226 DOI: 10.1016/j.amjoto.2021.103033 Abstract Objectives: Anosmia is a common debilitating symptom of the novel coronavirus disease 2019 (COVID-19). Currently, there is no satisfactory treatment of anosmia. Therefore, this study was conducted to evaluate the therapeutic effect of nasal betamethasone drops in the recovery of olfaction [...]

Authors: Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ PMID: 33836148 PMCID: PMC8023694 DOI: 10.1016/S2215-0366(21)00084-5 Abstract Background: Neurological and psychiatric sequelae of COVID-19 have been reported, but more data are needed to adequately assess the effects of COVID-19 on brain health. We aimed to provide robust estimates of incidence rates and relative risks [...]

Authors: Shoaibi A, Fortin S, Weinstein R, Berlin JA PMID: 33982938 DOI: 10.14309/ajg.0000000000001153 Abstract Introduction: Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, [...]

Authors: Watchorn J, Hang DY, Joslin J, Bramham K, Hutchings SD PMID: 32890313 DOI: 10.1097/SHK.0000000000001659 Abstract Background: Acute kidney injury (AKI) is a common complication of COVID-19 critical illness but the pathophysiology is uncertain. Some evidence has indicated that a vascular aetiology may be implicated. We used contrast-enhanced ultrasound (CEUS) and echocardiography to study renal [...]

Authors: Aveyard P, Gao M, Lindson N, Young D, Tan PS, Clift AK PMID: 33812494 PMCID: PMC8016404 DOI: 10.1016/S2213-2600(21)00095-3 Abstract Background: Previous studies suggested that the prevalence of chronic respiratory disease in patients hospitalised with COVID-19 was lower than its prevalence in the general population. The aim of this study was [...]

Authors: Doaei S, Gholami S, Rastgoo S, Bourbour F, Ghorat F, Joola P PMID: 33781275 PMCID: PMC8006115 DOI: 10.1186/s12967-021-02795-5 Abstract Background: Omega-3 polyunsaturated fatty acids (n3-PUFAs) may exert beneficial effects on the immune system of patients with viral infections. This paper aimed to examine the effect of n3-PUFA supplementation on inflammatory and biochemical markers in [...]

Authors: Ponti G, Roli L, Oliva G, Manfredini M, Trenti T, Kaleci S et al. doi: https://doi.org/10.1515/cclm-2021-0168 Abstract The Covid-19 pandemic is a global challenge, with rapidly increasing cases from the high infective aetiological agent, the Covid-19 virus. In October 2020, over 48 million confirmed Covid-19 cases and one million deaths were confirmed (www.who.int). There [...]